{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:10:06Z","timestamp":1759104606515,"version":"3.44.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Prostate adenocarcinoma (PRAD) is asymptomatic in the early stages and most patients are diagnosed at an advanced stage, which leads to a poor prognosis. Therefore, an effective prognostic marker is required to improve PRAD prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 128 patients with PRAD were included in the study. PSMA3-AS1 and miR-29a-3p expression in tissues was detected using RT-qPCR. CCK-8 and Transwell assays were then used to evaluate the proliferative, migratory, and invasive capacities of prostate cancer cell lines. A DLR assay confirmed the binding relationship between PSMA3-AS1 and miR-29a-3p. The five-year prognosis of PRAD patients was analyzed using a Kaplan\u2013Meier plotter curve.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>PSMA3-AS1 was highly expressed in PRAD tissues, and patients with high expression had poor 5-year survival. In contrast, miR-29a-3p was poorly expressed in PRAD tissues. PSMA3-AS1 bound to miR-29a-3p in a targeted manner and the levels showed a negative correlation. Knocking down PSMA3-AS1 could increase the level of miR-29a-3p and slow the proliferation of PRAD cell lines, as well as inhibiting their migration and invasion ability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A high level of PSMA3-AS1 was strongly linked to a poor prognosis for patients and is expected to serve as a prognostic marker for PRAD. Furthermore, PSMA3-AS1 knockdown increased the level of miR-29a-3p and reduced the physiological activity of cancer cells. Therefore, regulating the expression of the PSMA3-AS1\/miR-29a-3p axis could influence PRAD development.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41065-025-00485-6","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T13:35:59Z","timestamp":1752327359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of LncRNA PSMA3-AS1 in prostate cancer and its potential regulatory mechanism"],"prefix":"10.1186","volume":"162","author":[{"given":"Muyang","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"485_CR1","doi-asserted-by":"crossref","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024; 286\u201328718.","DOI":"10.20944\/preprints202401.1989.v1"},{"issue":"11","key":"485_CR2","doi-asserted-by":"publisher","first-page":"e073983","DOI":"10.1136\/bmjopen-2023-073983","volume":"13","author":"C Wang","year":"2023","unstructured":"Wang C, Dong Q, Liu X, Ni M, Xie Q, Xiao J, et al. Protocol for SNOTOB study: radical prostatectomy without prostate biopsy following (18)F-PSMA-1007 PET\/CT based on a diagnostic model: a single-centre, single-arm, open-label study. BMJ Open. 2023;13(11):e073983.","journal-title":"BMJ Open"},{"issue":"1","key":"485_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s41065-025-00443-2","volume":"162","author":"F Yang","year":"2025","unstructured":"Yang F, Qin Q, Liu J. Predictive value of microRNA-133a-3p for early urinary incontinence after radical prostatectomy for prostate cancer and its correlation with rehabilitation effects. Hereditas. 2025;162(1):75.","journal-title":"Hereditas"},{"issue":"1","key":"485_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41065-020-00125-1","volume":"157","author":"L Yin","year":"2020","unstructured":"Yin L, Yue C, Jing H, Yu H, Zuo L, Liu T. No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor-\u03b1 gene and susceptibility to prostate cancer: a comprehensive meta-analysis. Hereditas. 2020;157(1):11.","journal-title":"Hereditas"},{"key":"485_CR5","doi-asserted-by":"crossref","unstructured":"Chauhan K, Ebner DK, Tzou K, Ryan K, May J, Kaleem T et al. Assessment of bladder filling during prostate cancer radiation therapy with ultrasound and cone-beam CT. Front Oncol. 2023; 131200270.","DOI":"10.3389\/fonc.2023.1200270"},{"issue":"50","key":"485_CR6","doi-asserted-by":"publisher","first-page":"e36605","DOI":"10.1097\/MD.0000000000036605","volume":"102","author":"Z Liu","year":"2023","unstructured":"Liu Z, Kuang S, Chen Q. A review focusing on the role of pyroptosis in prostate cancer. Med (Baltim). 2023;102(50):e36605.","journal-title":"Med (Baltim)"},{"key":"485_CR7","doi-asserted-by":"crossref","unstructured":"Jomy J, Sharma R, Lu R, Chen D, Ataalla P, Kaushal S et al. Clinical impact of radiotherapy quality assurance results in contemporary cancer trials: a systematic review and meta-analysis. Radiother Oncol. 2025; 207110875.","DOI":"10.2139\/ssrn.5034955"},{"issue":"3","key":"485_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/00325481.2024.2345585","volume":"136","author":"Y Sun","year":"2024","unstructured":"Sun Y, Gong J, Li Z, Han L, Sun D. Gallbladder cancer: surgical treatment, immunotherapy, and targeted therapy. Postgrad Med. 2024;136(3):278\u201391.","journal-title":"Postgrad Med"},{"issue":"Pt 1","key":"485_CR9","doi-asserted-by":"publisher","first-page":"143497","DOI":"10.1016\/j.ijbiomac.2025.143497","volume":"311","author":"S Gao","year":"2025","unstructured":"Gao S, Xu T, Wang W, Li J, Shan Y, Wang Y, et al. Polysaccharides from anemarrhena asphodeloides bge, the extraction, purification, structure characterization, biological activities and application of a traditional herbal medicine. Int J Biol Macromol. 2025;311(Pt 1):143497.","journal-title":"Int J Biol Macromol"},{"key":"485_CR10","doi-asserted-by":"crossref","unstructured":"Khan SR, Breadner D. Unveiling the synergistic potential: bispecific antibodies in conjunction with chemotherapy for advanced Non-Small-Cell lung Cancer treatment. Curr Oncol. 2025; 32(4).","DOI":"10.3390\/curroncol32040206"},{"key":"485_CR11","doi-asserted-by":"crossref","unstructured":"Ma Z, Liu X, Zhang X, Li S, An J, Luo Z. Research progress on long non\u2013coding RNAs in non\u2013infectious spinal diseases (Review). Mol Med Rep. 2024; 30(3).","DOI":"10.3892\/mmr.2024.13288"},{"issue":"17","key":"485_CR12","doi-asserted-by":"publisher","first-page":"8095","DOI":"10.1111\/jcmm.16808","volume":"25","author":"X Dong","year":"2021","unstructured":"Dong X, Cong S. The emerging roles of long non-coding RNAs in polyglutamine diseases. J Cell Mol Med. 2021;25(17):8095\u2013102.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"485_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s41065-025-00445-0","volume":"162","author":"C Zhou","year":"2025","unstructured":"Zhou C, Qiu Q, Liu X, Zhang T, Liang L, Yuan Y, et al. Novel exosome-associated LncRNA model predicts colorectal cancer prognosis and drug response. Hereditas. 2025;162(1):79.","journal-title":"Hereditas"},{"issue":"1","key":"485_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1354750X.2022.2142293","volume":"28","author":"Y Li","year":"2023","unstructured":"Li Y, Wei C, Huang C, Ling Q, Zhang L, Huang S, et al. Long noncoding RNA as a potential diagnostic tool for prostate cancer: a systematic review and meta-analysis. Biomarkers. 2023;28(1):1\u201310.","journal-title":"Biomarkers"},{"key":"485_CR15","doi-asserted-by":"crossref","unstructured":"Cao X, Luan K, Yang J, Huang Y. Targeting LncRNA PSMA3-AS1, a prognostic marker, suppresses malignant progression of oral squamous cell carcinoma. Dis Markers. 2021; 20213138046.","DOI":"10.1155\/2021\/3138046"},{"key":"485_CR16","doi-asserted-by":"crossref","unstructured":"Syllaios A, Gazouli M, Vailas M, Mylonas KS, Sakellariou S, Sougioultzis S et al. The expression patterns and implications of MALAT1, MANCR, PSMA3-AS1 and miR-101 in esophageal adenocarcinoma. Int J Mol Sci. 2023; 25(1).","DOI":"10.3390\/ijms25010098"},{"issue":"10","key":"485_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.17219\/acem\/138624","volume":"30","author":"G Cheng","year":"2021","unstructured":"Cheng G, Li Y, Liu Z, Song X. LncRNA PSMA3-AS1 promotes the progression of non-small cell lung cancer through targeting miR-17-5p\/PD-L1. Adv Clin Exp Med. 2021;30(10):1043\u201350.","journal-title":"Adv Clin Exp Med"},{"issue":"22","key":"485_CR18","first-page":"11594","volume":"24","author":"P Peng","year":"2020","unstructured":"Peng P, Wang Y, Wang BL, Song YH, Fang Y, Ji H, et al. LncRNA PSMA3-AS1 promotes colorectal cancer cell migration and invasion via regulating miR-4429. Eur Rev Med Pharmacol Sci. 2020;24(22):11594\u2013601.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"485_CR19","doi-asserted-by":"crossref","unstructured":"Retraction. Long non-coding RNA PSMA3-AS1 enhances cell proliferation, migration and invasion by regulating miR-302a-3p\/RAB22A in glioma. Biosci Rep. 2023; 43(3).","DOI":"10.1042\/BSR-2019-1571_RET"},{"issue":"2","key":"485_CR20","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.1080\/21655979.2021.1994907","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Xu Y, Yin S, Qiu F. YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for MicroRNA 214-5p to expedite the viability and restrict the apoptosis of bladder cancer cells via regulating programmed cell death-ligand 1. Bioengineered. 2021;12(2):9150\u201361.","journal-title":"Bioengineered"},{"issue":"1","key":"485_CR21","doi-asserted-by":"publisher","first-page":"101484","DOI":"10.1016\/j.bjorl.2024.101484","volume":"91","author":"G Yin","year":"2025","unstructured":"Yin G, Guo W, Wang R, Li N, Chen X, Zhang Y, et al. Analysis of the role of IL-1 family and related genes in head and neck squamous cell carcinoma. Braz J Otorhinolaryngol. 2025;91(1):101484.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"11","key":"485_CR22","doi-asserted-by":"publisher","first-page":"e21506","DOI":"10.1016\/j.heliyon.2023.e21506","volume":"9","author":"S Xiao","year":"2023","unstructured":"Xiao S, Lou W. Integrated analysis reveals a potential cuproptosis-related CeRNA axis SNHG17\/miR-29a-3p\/GCSH in prostate adenocarcinoma. Heliyon. 2023;9(11):e21506.","journal-title":"Heliyon"},{"issue":"1","key":"485_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/jcmm.14791","volume":"24","author":"Z Kong","year":"2020","unstructured":"Kong Z, Wan X, Lu Y, Zhang Y, Huang Y, Xu Y, et al. Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p. J Cell Mol Med. 2020;24(1):799\u2013813.","journal-title":"J Cell Mol Med"},{"key":"485_CR24","doi-asserted-by":"crossref","unstructured":"Zhu W, Liu H, Wang X, Lu J, Zhang H, Wang S et al. Associations of CYP1 polymorphisms with risk of prostate cancer: an updated meta-analysis. Biosci Rep. 2019; 39(3).","DOI":"10.1042\/BSR20181876"},{"issue":"1","key":"485_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jcmm.17641","volume":"27","author":"J Han","year":"2023","unstructured":"Han J, Zhou Y, Zhang C, Feng J, Wang J, Guo K, et al. Intratumoral immune heterogeneity of prostate cancer characterized by typing and hub genes. J Cell Mol Med. 2023;27(1):101\u201312.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"485_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.5483\/BMBRep.2023-0075","volume":"56","author":"SH Han","year":"2023","unstructured":"Han SH, Ko JY, Kang ES, Park JH, Yoo KH. Long non-coding rnas: key regulators of liver and kidney fibrogenesis. BMB Rep. 2023;56(7):374\u201384.","journal-title":"BMB Rep"},{"key":"485_CR27","doi-asserted-by":"crossref","unstructured":"Yang J, Liu K, Chen L, He H, Li T, Li L et al. Revisiting the role of long Non-coding RNA PSMA3-AS1 in human cancers: current evidence and future directions. Curr Pharm Des. 2025.","DOI":"10.2174\/0113816128350406241223053744"},{"issue":"14","key":"485_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.14715\/cmb\/2023.69.14.13","volume":"69","author":"M Peng","year":"2023","unstructured":"Peng M, Yuan H. LncRNA PSMA3-AS1 activates the progression of triple-negative breast cancer cells by blocking miR-186-5p-mediated PSME3 Inhibition. Cell Mol Biol (Noisy-le-grand). 2023;69(14):81\u20137.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"1","key":"485_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13062-023-00392-8","volume":"18","author":"L Kan","year":"2023","unstructured":"Kan L, Yang M, Zhang H. Long noncoding RNA PSMA3-AS1 functions as a competing endogenous RNA to promote gastric cancer progression by regulating the miR-329-3p\/ALDOA axis. Biol Direct. 2023;18(1):36.","journal-title":"Biol Direct"},{"key":"485_CR30","doi-asserted-by":"crossref","unstructured":"Jahangiri L. Updates on liquid biopsies in neuroblastoma for treatment response, relapse and recurrence assessment. Cancer Genet. 2024; 288\u201328932.","DOI":"10.1016\/j.cancergen.2024.09.001"},{"key":"485_CR31","doi-asserted-by":"crossref","unstructured":"Ohyama H, Hirotsu Y, Amemiya K, Mikata R, Amano H, Hirose S et al. Development of a molecular barcode detection system for pancreaticobiliary malignancies and comparison with next-generation sequencing. Cancer Genet. 2024; 280\u20132816.","DOI":"10.1016\/j.cancergen.2023.12.002"},{"key":"485_CR32","doi-asserted-by":"crossref","unstructured":"Gonzalez T, Nie Q, Chaudhary LN, Basel D, Reddi HV. Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature. Cancer Genet. 2024; 282\u20132831.","DOI":"10.1016\/j.cancergen.2023.12.003"},{"issue":"12","key":"485_CR33","doi-asserted-by":"publisher","first-page":"101857","DOI":"10.1016\/j.isci.2020.101857","volume":"23","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang R, Wu S, Shen L, Ke M, Ouyang Y, et al. Super-Enhancer LncRNA LINC00162 promotes progression of bladder Cancer. iScience. 2020;23(12):101857.","journal-title":"iScience"},{"key":"485_CR34","doi-asserted-by":"crossref","unstructured":"Liu J, Zhang Y, Wu J, Liu X, Li L, Zhang J. LncRNA FOXD2-AS1 promotes the growth, invasion and migration of OSCC cells by regulating the MiR-185-5p\/PLOD1\/Akt\/mTOR pathway. Cancer Genet. 2024; 284\u201328548.","DOI":"10.1016\/j.cancergen.2024.05.001"},{"issue":"8","key":"485_CR35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/MPA.0000000000002136","volume":"51","author":"J Bi","year":"2022","unstructured":"Bi J, Liang W, Wang Y, Tian W, Cao S, Liu P, Long Noncoding. RNA PSMA3 antisense RNA 1 promotes cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via targeting MicroRNA-154-5p to positively modulate Karyopherin subunit alpha 4. Pancreas. 2022;51(8):1037\u201346.","journal-title":"Pancreas"},{"issue":"1","key":"485_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.18632\/aging.203828","volume":"14","author":"D Sun","year":"2022","unstructured":"Sun D, Li F, Liu L, Yu S, Wang H, Gao X, et al. PSMA3-AS1 induced by transcription factor PAX5 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-376a-3p to up-regulate LAMC1. Aging. 2022;14(1):509\u201325.","journal-title":"Aging"},{"key":"485_CR37","doi-asserted-by":"crossref","unstructured":"Li F, Yu L, Zhu J. LncRNA PSMA3-AS1 promotes lung Cancer growth and invasion via sponging MiR-4504. Cancer Manag Res. 2020; 125277\u201383.","DOI":"10.2147\/CMAR.S253575"},{"key":"485_CR38","doi-asserted-by":"crossref","unstructured":"Li X, Lv X, Li Z, Li C, Li X, Xiao J et al. Long noncoding RNA ASLNC07322 functions in VEGF-C expression regulated by Smad4 during Colon cancer metastasis. Mol Ther Nucleic Acids. 2019; 18851\u201362.","DOI":"10.1016\/j.omtn.2019.10.012"},{"issue":"3","key":"485_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/1759-7714.13304","volume":"11","author":"L Yu","year":"2020","unstructured":"Yu L, Chen D, Song J. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p. Thorac Cancer. 2020;11(3):603\u201311.","journal-title":"Thorac Cancer"},{"issue":"1","key":"485_CR40","doi-asserted-by":"publisher","first-page":"8570","DOI":"10.1080\/21655979.2021.1987126","volume":"12","author":"Y Guo","year":"2021","unstructured":"Guo Y, Liu Y, Wang H, Liu P. Long noncoding RNA SRY-box transcription factor 2 overlapping transcript participates in parkinson\u2019s disease by regulating the microRNA-942-5p\/nuclear apoptosis-inducing factor 1 axis. Bioengineered. 2021;12(1):8570\u201382.","journal-title":"Bioengineered"},{"key":"485_CR41","doi-asserted-by":"crossref","unstructured":"Chen Y, Zheng J, Su L, Chen F, Zhu R, Chen X et al. Increased Salivary microRNAs That Regulate DJ-1 Gene Expression as Potential Markers for Parkinson\u2019s Disease. Front Aging Neurosci. 2020; 12210.","DOI":"10.3389\/fnagi.2020.00210"},{"issue":"15","key":"485_CR42","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.7150\/thno.33683","volume":"9","author":"D He","year":"2019","unstructured":"He D, Wang H, Ho SL, Chan HN, Hai L, He X, et al. Total internal reflection-based single-vesicle in situ quantitative and stoichiometric analysis of tumor-derived Exosomal MicroRNAs for diagnosis and treatment monitoring. Theranostics. 2019;9(15):4494\u2013507.","journal-title":"Theranostics"},{"issue":"1","key":"485_CR43","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1186\/s12885-022-10263-6","volume":"22","author":"H Zhang","year":"2022","unstructured":"Zhang H, Du Y, Xin P, Man X. The LINC00852\/miR-29a-3p\/JARID2 axis regulates the proliferation and invasion of prostate cancer cell. BMC Cancer. 2022;22(1):1269.","journal-title":"BMC Cancer"},{"key":"485_CR44","doi-asserted-by":"crossref","unstructured":"Liu Z, Guo N, Zhang XJ. Long noncoding TUG1 promotes angiogenesis of HUVECs in PE via regulating the miR-29a-3p\/VEGFA and Ang2\/Tie2 pathways. Microvasc Res. 2022; 139104231.","DOI":"10.1016\/j.mvr.2021.104231"},{"issue":"10","key":"485_CR45","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1111\/jog.15360","volume":"48","author":"H Xu","year":"2022","unstructured":"Xu H, Tang Y, He C, Tian Y, Ni R. Prognostic value of LncRNA HOXA-AS3 in cervical cancer by targeting miR-29a-3p and its regulatory effect on tumor progression. J Obstet Gynaecol Res. 2022;48(10):2594\u2013602.","journal-title":"J Obstet Gynaecol Res"},{"issue":"8","key":"485_CR46","doi-asserted-by":"publisher","first-page":"167454","DOI":"10.1016\/j.bbadis.2024.167454","volume":"1870","author":"MM Li","year":"2024","unstructured":"Li MM, Shi MJ, Feng CC, Yu ZY, Bai XF, Lu L. LncRNA KCNQ1OT1 promotes NLRP3 inflammasome activation in parkinson\u2019s disease by regulating pri-miR-186\/mature miR-186\/NLRP3 axis. Biochim Biophys Acta Mol Basis Dis. 2024;1870(8):167454.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"12","key":"485_CR47","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/14728222.2023.2293750","volume":"27","author":"W Zhang","year":"2023","unstructured":"Zhang W, Nie Q, Zhang X, Huang L, Pang G, Chu J, et al. miR-26a-5p restoration via EZH2 Silencing blocks the IL-6\/STAT3 axis to repress the growth of prostate cancer. Expert Opin Ther Targets. 2023;27(12):1285\u201397.","journal-title":"Expert Opin Ther Targets"},{"issue":"3\u20134","key":"485_CR48","first-page":"Cbm240119","volume":"41","author":"Rasteh","year":"2024","unstructured":"Rasteh AM, Liu H, Wang. Pan-cancer genetic profiles of mitotic DNA integrity checkpoint protein kinases. Cancer Biomark. 2024;41(3\u20134):Cbm240119.","journal-title":"Cancer Biomark"},{"issue":"5","key":"485_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10142-024-01443-7","volume":"24","author":"H Liu","year":"2024","unstructured":"Liu H, Weng J, Huang CL, Jackson AP. Is the voltage-gated sodium channel \u03b23 subunit (SCN3B) a biomarker for glioma? Funct Integr Genomics. 2024;24(5):162.","journal-title":"Funct Integr Genomics"},{"issue":"1","key":"485_CR50","doi-asserted-by":"publisher","first-page":"19055","DOI":"10.1038\/s41598-023-45774-0","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu H, Tang T. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Sci Rep. 2023;13(1):19055.","journal-title":"Sci Rep"},{"issue":"1","key":"485_CR51","doi-asserted-by":"publisher","first-page":"19142","DOI":"10.1038\/s41598-024-70184-1","volume":"14","author":"H Liu","year":"2024","unstructured":"Liu H, Dong A, Rasteh AM, Wang P, Weng J. Identification of the novel exhausted T cell CD8\u2009+\u2009markers in breast cancer. Sci Rep. 2024;14(1):19142.","journal-title":"Sci Rep"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00485-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00485-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T06:32:59Z","timestamp":1757226779000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00485-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["485"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00485-6","relation":{},"ISSN":["1601-5223"],"issn-type":[{"type":"electronic","value":"1601-5223"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Shanxi Province Cancer Hospital before the study began. The written informed consent has been obtained from the participants involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"127"}}